Access to information and expectations of treatment decisions for prostate cancer patients - results of a European survey

2013 ◽  
Vol 22 (2) ◽  
pp. 210-218 ◽  
Author(s):  
B. Tombal ◽  
E. Baskin-Bey ◽  
C. Schulman
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Decisions ◽  
Access To Information ◽  
European Survey

Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. e16042-e16042
Author(s):  
Neal Shore ◽  
Judd Boczko ◽  
Naveen Kella ◽  
Brian Joseph Moran ◽  
Fernando J. Bianco ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Decisions ◽  
Newly Diagnosed

scholarly journals Making their decisions for prostate cancer treatment: Patients’ experiences and preferences related to process

2018 ◽  
Vol 12 (10) ◽  
Author(s):  
Deb Feldman-Stewart ◽  
Christine Tong ◽  
Michael Brundage ◽  
Jackie Bender ◽  
John Robinson
Keyword(s):  
Prostate Cancer ◽  
Decision Support ◽  
Cancer Patients ◽  
Decision Aid ◽  
Decision Aids ◽  
Treatment Decisions ◽  
Prostate Cancer Treatment ◽  
Total N ◽  
Canadian Provinces ◽  
Recruiting Strategy

Introduction: We sought to determine the experiences and preferences of prostate cancer patients related to the process of making their treatment decisions, and to the use of decision support.Methods: Population surveys were conducted in four Canadian provinces in 2014–2015. Each provincial cancer registry mailed surveys to a random sample of their prostate cancer patients diagnosed in late 2012. Three registries’ response rates were 46–55%; the fourth used a different recruiting strategy, producing a response rate of 13% (total n=1366).Results: Overall, 90% (n=1113) of respondents reported that they were involved in their treatment decisions. Twenty-three percent (n=247) of respondents wanted more help with the decision than they received and 52% of them (n=128) reported feeling wellinformed. Only 51% (n=653) of all respondents reported receiving any decision support, but an additional 34% (n=437) would want to if they were aware of its existence. A quarter (25%, n=316) of respondents found it helpful to use a decision aid, a type of decision support that provides assistance to decision processes and provides information, but 64% (n=828) reported never having heard of decision aids; 26% (n=176) of those who had never heard of decision aids wanted more help with the decision than they received compared to 13% (n=36) of those who had used a decision aid.Conclusions: The majority of respondents wanted to participate in their treatment decisions, but a portion wanted more help than they received. Half of those who wanted more help felt well-informed, thus, needed support beyond information. Decision aids have potential to provide information and support to the decision process.

Reduction in therapeutic burden from use of CCP test in treatment decisions among newly diagnosed prostate cancer patients independent of Charlson Comorbidity Index.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16572-e16572
Author(s):  
Neal D. Shore ◽  
E. David Crawford ◽  
Matthew R. Cooperberg ◽  
Jonathan D. Tward ◽  
Rajesh R. Kaldate ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Charlson Comorbidity Index ◽  
Treatment Decisions ◽  
Newly Diagnosed ◽  
Comorbidity Index

scholarly journals Association of Pre-Existing Symptoms with Treatment Decisions among Newly Diagnosed Prostate Cancer Patients

2008 ◽  
Vol 1 (3) ◽  
pp. 189-200 ◽  
Author(s):  
Steven B Zeliadt ◽  
Scott D Ramsey ◽  
Arnold L Potosky ◽  
Neeraj K Arora ◽  
David K Blough ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Decisions ◽  
Newly Diagnosed

Determining value of high cost cancer therapies and discussing cost of cancer care: The patient perspective.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6512-6512
Author(s):  
Saurabh Rajguru ◽  
Lakeesha Carmichael ◽  
Jeremy Paul Cetnar
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Treatment Decisions ◽  
Treatment Costs ◽  
Cancer Therapies ◽  
Annual Household Income ◽  
A Value ◽  
Hypothetical Scenario ◽  
Clinical Benefits ◽  
Out Of Pocket Expenses

6512 Background: A trend in cancer treatment is the growing number of high-priced therapies which offer marginal clinical benefits. This has led ASCO to issue guidelines stressing the importance of discussing treatment costs with patients. There are many identified barriers which limit communication of cost including oncologists’ fears that patients may view this discussion as inappropriate. We attempted to assess cancer patients’ views on discussion of treatment costs with their oncologists, as well as, their views on high-cost drugs (HCDs), including the belief that there is a cohort of patients who would forgo high-priced treatment even if there was no out-of-pocket expense. Methods: We surveyed patients with advanced prostate cancer. The survey consisted of demographic information and an 11-item questionnaire. We also gave them a hypothetical scenario in which they were asked how much they would be willing-to-pay (WTP) for a $100K drug that would improve survival on average by four months with minimal side-effects (modeled after Provenge). The survey was administered to patients in clinic prior to their visit. Results: Of the patients approached, 169 responded (88% response rate). Seventeen percent stated they would not want treatment with HCDs even if they had no out-of-pocket expenses (more likely to be older (>70) and have an annual household income of >$60K). Another 21% stated they would accept treatment only if they had no out-of-pocket expenses. The median WTP for the hypothetical drug was $20K. Most patients (79%) agree that a discussion of costs with their physician is appropriate and 69% would want to have this discussion. Most patients (82%) agree that prognosis is important when making treatment decisions however 66% of patients did not know their cancer stage. Only 37% agree that the oncologist or the patient should consider the country’s healthcare costs when making treatment decisions. Conclusions: Prostate cancer patients clearly want to have discussions regarding costs-of-care with their oncologists. There is a group who would forgo treatment with high-cost drugs that yield only modest survival benefits. Their motivation is unknown, but is hypothesized to reflect a value-based judgment.

390: Durable Cancer Control in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy

2007 ◽  
Vol 177 (4S) ◽  
pp. 130-130
Author(s):  
Markus Graefen ◽  
Jochen Walz ◽  
Andrea Gallina ◽  
Felix K.-H. Chun ◽  
Alwyn M. Reuther ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Cancer Control ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

598: Increased Risk of Newly Diagnosed Comorbidities in Prostate Cancer Patients Treated with Androgen Deprivation Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 200-200 ◽  
Author(s):  
Andrea Gallina ◽  
Pierre I. Karakiewicz ◽  
Jochen Walz ◽  
Claudio Jeldres ◽  
Quoc-Dien Trinh ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Androgen Deprivation Therapy ◽  
Androgen Deprivation ◽  
Newly Diagnosed ◽  
Increased Risk
Sign in / Sign up

Export Citation Format

Share Document